Drug intelligence / Profile preview

BlephaCura

Development stage: Unknown
Lead developer: Circius Pharma
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

BlephaCura is an over-the-counter (OTC) eyelid cleansing solution developed and marketed by Circius Pharma, a Swedish pharmaceutical and MedTech company. It is specifically formulated for the daily hygiene and care of irritated or sensitive eyelids, as well as for the relief and treatment of blepharitis (eyelid inflammation). The solution works by cleaning the eyelid margins and the surrounding eye area, helping to remove crusts and secretions while supporting the natural healing process of inflamed tissues. It is primarily marketed in Scandinavian countries as part of a consumer health portfolio focused on patient-centered eye and ear care.

Brand names: BlephaCura
Other names: Blephacura

Beyond the preview

Go deeper on BlephaCura.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BlephaCura.

Explore the full profile